Company: IR
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001628280-25-006391
Chunk: 53

Company: Ingersoll Rand Inc.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 53
---
0)(655.6)Proceeds from long-term debt3,296.9 1,490.4 — Purchases of treasury stock(260.7)(263.0)(261.1)Cash dividends on common stock(32.3)(32.4)(32.4)Proceeds from stock option exercises32.2 30.3 19.3 Payments to settle cross-currency swaps(19.9)— — Payments of interest rate cap premiums— — (13.4)Payments of deferred and contingent acquisition consideration(23.4)(17.5)(4.6)Payments of debt issuance costs(32.3)(18.5)— Other financing(10.3)(8.8)(6.2)Net cash (used in) provided by financing activities from continuing operations1,707.5 (337.5)(954.0)Cash Flows Used In Discontinued OperationsNet cash used in operating activities— — (5.1)Net cash provided by investing activities— — 4.4 Net cash used in discontinued operations— — (0.7)Effect of exchange rate changes on cash and cash equivalents(50.8)3.1 (70.0)Net decrease in cash and cash equivalents(54.3)(17.5)(496.6)Cash and cash equivalents, beginning of year1,595.5 1,613.0 2,109.6 Cash and cash equivalents, end of year$1,541.2 $1,595.5 $1,613.0 

42

For the Years Ended December 31,202420232022Supplemental Cash Flow InformationCash paid for income taxes, net of refunds$276.7 $302.0 $181.5 Cash paid for interest, net of interest rate derivative settlements209.0 100.5 95.2 

The accompanying notes are an integral part of these consolidated financial statements.

43

INGERSOLL RAND INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in millions, except share and per share amounts)

Note 1:    Summary of Significant Accounting Policies

Overview and Basis of PresentationIngersoll Rand Inc. is a global provider of mission-critical flow creation products and life science and industrial solutions. The accompanying consolidated financial statements include the accounts of Ingersoll Rand